0000880771-16-000185.txt : 20160816 0000880771-16-000185.hdr.sgml : 20160816 20160816174107 ACCESSION NUMBER: 0000880771-16-000185 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160812 FILED AS OF DATE: 20160816 DATE AS OF CHANGE: 20160816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blobel Friedhelm CENTRAL INDEX KEY: 0001363213 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 161836979 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 certent-form4.xml PRIMARY DOCUMENT X0306 4 2016-08-12 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001363213 Blobel Friedhelm 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 1 0 0 President & CEO Common Stock 2016-08-12 4 M 0 3500 0 A 463782 D Common Stock 2016-08-12 4 M 0 5000 0 A 468782 D Common Stock 2016-08-12 4 M 0 50000 0 A 518782 D Common Stock 2016-08-12 4 F 0 1827 10.41 D 516955 D Common Stock 2016-08-12 4 F 0 26090 10.41 D 490865 D Common Stock 2016-08-12 4 F 0 2610 10.41 D 488255 D Restricted Stock Unit 2016-08-12 4 A 0 40000 0 A Common Stock 40000 383500 D Restricted Stock Unit 2016-08-12 4 M 0 3500 0 D Common Stock 3500 380000 D Restricted Stock Unit 2016-08-12 4 M 0 5000 0 D Common Stock 5000 375000 D Restricted Stock Unit 2016-08-12 4 M 0 50000 0 D Common Stock 50000 325000 D Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2016. Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units. Granted under the Issuer's 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock. Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017. Granted under the Issuer's 2005 Equity Incentive Plan. Vesting for such RSUs will occur 50% on February 20, 2015 and 50% on February 20, 2016, or on such later date thereafter as the Company's trading window opens if it is not open on either of such dates. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment. Vesting to be in three equal annual installments at the close of business on the first business day following December 31 of each of calendar year 2015, 2016, and 2017, provided that the Participant's service with the Company has not terminated prior to the applicable vesting time. Friedhelm Blobel, Ph.D. 2016-08-16